Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer Patients.

breast cancer neonatal outcomes obstetrical outcomes time to pregnancy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
03 Mar 2021
Historique:
received: 02 02 2021
revised: 23 02 2021
accepted: 24 02 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

Although an increasing number of young breast cancer (BC) patients have a pregnancy desire after BC, the time necessary to obtain a pregnancy after treatment and subsequent outcomes remain unknown. We aimed to determine the time to evolutive pregnancy in a cohort of BC survivors and subsequent obstetrical and neonatal outcomes. We analyzed BC patients treated at Institut Curie from 2005-2017, aged 18-43 years old (y.o.) at diagnosis having at least one subsequent pregnancy. 133 patients were included, representing 197 pregnancies. Mean age at BC diagnosis was 32.8 y.o. and at pregnancy beginning was 36.8 y.o. 71% pregnancies were planned, 18% unplanned and 86% spontaneous. 64% pregnancies resulted in live birth (

Identifiants

pubmed: 33802333
pii: cancers13051070
doi: 10.3390/cancers13051070
pmc: PMC7959151
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Clin Oncol. 1999 May;17(5):1474-81
pubmed: 10334533
Bull Cancer. 2020 Sep;107(9):854-860
pubmed: 32762944
Future Oncol. 2014 Aug;10(10):1767-77
pubmed: 25303056
J Obstet Gynaecol Can. 2016 Jul;38(7):667-679.e1
pubmed: 27591352
J Clin Oncol. 2016 Jul 1;34(19):2232-8
pubmed: 27161974
BMJ. 2000 Jun 24;320(7251):1708-12
pubmed: 10864550
J Clin Oncol. 2020 Sep 10;38(26):3012-3023
pubmed: 32673153
Clin Breast Cancer. 2008 Feb;8(1):65-9
pubmed: 18501060
PLoS Med. 2006 Sep;3(9):e336
pubmed: 16968117
Am J Obstet Gynecol. 1994 Mar;170(3):818-23
pubmed: 8141209
NCHS Data Brief. 2016 Jan;(232):1-8
pubmed: 26828319
Front Endocrinol (Lausanne). 2020 Dec 08;11:572388
pubmed: 33363515
BMJ. 2007 Jan 27;334(7586):194
pubmed: 17158581
Am J Obstet Gynecol. 2017 Dec;217(6):667.e1-667.e8
pubmed: 28917614
J Clin Oncol. 2016 Sep 20;34(27):3308-14
pubmed: 27480155
Breast Cancer Res. 2014 Aug 27;16(4):427
pubmed: 25436920
Clin Breast Cancer. 2018 Feb;18(1):e79-e88
pubmed: 28797766
Hum Reprod Update. 2011 Nov-Dec;17(6):848-60
pubmed: 21652599
J Natl Cancer Inst. 2018 Apr 01;110(4):426-429
pubmed: 29087485
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Int J Cancer. 2017 Dec 1;141(11):2187-2196
pubmed: 28836277
Cancer. 2021 Apr 1;127(7):1021-1028
pubmed: 33259061
Acta Oncol. 2008;47(4):545-9
pubmed: 18465320
Breast. 2009 Dec;18(6):345-50
pubmed: 19892553
Reprod Biomed Online. 2016 Mar;32(3):299-307
pubmed: 26803206
Int J Cancer. 2018 May 15;142(10):1994-2002
pubmed: 29266267
Breast. 2012 Jun;21(3):272-5
pubmed: 22018510
Ann Oncol. 2020 Jun;31(6):674-696
pubmed: 32199930
J Clin Oncol. 2018 Jul 1;36(19):1994-2001
pubmed: 29620997
Cancer. 1999 Jun 1;85(11):2424-32
pubmed: 10357413
JAMA Oncol. 2017 Aug 1;3(8):1078-1084
pubmed: 28334337
J Cancer Res Clin Oncol. 2017 Jun;143(6):1069-1074
pubmed: 28220257
Br J Cancer. 2006 Jan 16;94(1):142-6
pubmed: 16306874
Breast Cancer Res Treat. 2016 Nov;160(2):347-360
pubmed: 27683280
J Clin Oncol. 2008 Jul 10;26(20):3324-30
pubmed: 18612148
Fertil Steril. 2013 Jun;99(7):1958-64
pubmed: 23517858
NCHS Data Brief. 2009 Aug;(21):1-8
pubmed: 19674536
J Clin Oncol. 2001 Mar 15;19(6):1671-5
pubmed: 11250996
Eur J Cancer. 2015 Aug;51(12):1490-6
pubmed: 26070684
Fertil Steril. 2016 Jun;105(6):1584-1588.e1
pubmed: 26953733
JCO Clin Cancer Inform. 2019 Oct;3:1-12
pubmed: 31626565
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
J Clin Oncol. 2013 Jan 1;31(1):73-9
pubmed: 23169515
Cancer. 2003 Sep 15;98(6):1131-40
pubmed: 12973836
Cancers (Basel). 2019 Nov 14;11(11):
pubmed: 31739537
J Womens Health (Larchmt). 2019 Apr;28(4):544-550
pubmed: 29963941
Ann Oncol. 2020 Dec;31(12):1664-1678
pubmed: 32976936
Cancer. 2004 Feb 1;100(3):465-9
pubmed: 14745861
Lancet. 2010 Aug 21;376(9741):631-44
pubmed: 20598363

Auteurs

Julie Labrosse (J)

Department of Surgery, Institut Curie, 75005 Paris, France.

Anne Lecourt (A)

Department of Surgery, Institut Curie, 75005 Paris, France.

Alice Hours (A)

Department of Surgery, Institut Curie, 75005 Paris, France.

Clara Sebbag (C)

Department of Surgery, Institut Curie, 75005 Paris, France.

Aullene Toussaint (A)

Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France.

Enora Laas (E)

Department of Surgery, Institut Curie, 75005 Paris, France.

Florence Coussy (F)

Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France.

Beatriz Grandal (B)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, F-75005 Paris, France.

Elise Dumas (E)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, F-75005 Paris, France.

Eric Daoud (E)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, F-75005 Paris, France.

Charlotte Morel (C)

Department of Surgery, Institut Curie, 75005 Paris, France.

Jean-Guillaume Feron (JG)

Department of Surgery, Institut Curie, 75005 Paris, France.

Matthieu Faron (M)

Department of Biostatistics and Epidemiology, INSERM 1018 CESP Oncostat Team, Gustave, Roussy Cancer Campus, 94800 Villejuif, France.

Jean-Yves Pierga (JY)

Medical Oncology Department, Institut Curie, 75005 Paris, France.

Fabien Reyal (F)

Department of Surgery, Institut Curie, 75005 Paris, France.
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, F-75005 Paris, France.

Anne-Sophie Hamy (AS)

Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France.
Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, F-75005 Paris, France.

Classifications MeSH